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Abstract
Background—Aflibercept is a recombinantly-produced fusion protein that has potent anti-
VEGF activity. We tested whether aflibercept has clinical activity in clear cell renal cell carcinoma 
(ccRCC). The recommended Phase 2 dose was 4 mg/kg but several patients treated at 1 mg/kg 
demonstrated prolonged progression-free survival (PFS). We therefore tested both doses in a 
parallel group randomized trial.
Methods—Eligible patients (pts) had histologically confirmed advanced or metastatic ccRCC 
and previous treatments including prior exposure to a VEGF RTKI. Patients received aflibercept 
(either 1 mg/kg or 4 mg/kg) day 1 of a 14-day cycle until progression. Patients randomized to 1 
mg/kg could crossover to 4 mg/kg at progression. The primary endpoint was proportion alive and 
progression-free at 8 weeks. A Simon 2-stage design was used for each arm with 33 and 24 
eligible pts/arm enrolled in stages 1 and 2.
Results—94 pts were enrolled, 59 and 35 to 4 mg and 1 mg doses, respectively. 72% had 1 prior 
tx most commonly sunitinib. 16 eligible pts crossed over at progression to the 4 mg dose. Most 
common adverse events were hypertension, proteinuria, and fatigue. Only 4 pts reported Grade 4 
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or higher toxicity. With 36/59 (61%) pts PFS at 8 wks, the 4-mg/kg dose met protocol specified 
efficacy criteria.
Conclusions—Aflibercept is active in previously treated ccRCC and may be worthy of further 
study.
Keywords
renal cell carcinoma; antiangiogenesis; VEGF blocker
Introduction
Renal cell carcinoma is the fourth most common genitourinary cancer with approximately 
30,000 new cases diagnosed annually causing 12,000 deaths1. Approximately 45% of 
patients, at the time of diagnosis, have disease localized to their kidney; 30% have distant 
metastases; and 25% have locally advanced disease2. Surgical resection is the only 
potentially curative therapy. The five-year survival for stage I or II disease patients is 66%; 
42% for stage III disease; and less than 5% for stage IV disease2.
Angiogenesis, an orderly and tightly controlled process through which tumor is 
neovascularized, is required for metastasis and tumor progression. This process is controlled 
by multiple factors, one of which is the vascular endothelial growth factor (VEGF) – a 
protein that has a critical role in initiating and sustaining tumor angiogenesis. Clear cell 
renal cell carcinoma (ccRCC), the most common type of kidney cancer, harbor genetic and 
epigenetic alteration of the von Hippel- Lindau (VHL) gene and consequently the 
stabilization of the transcriptional factor hypoxia inducible factors (HIFs) with down-stream 
upregulation of VEGF2. Over the past 10 years the use of VEGF/VEGF receptor targeting 
drugs has changed the treatment of ccRCC. However, despite the proven clinical benefit, 
eventually patients develop progressive disease due to drug resistance.
Aflibercept has been developed as a decoy receptor and blocking drug with greater binding 
affinity to VEGF as compared to bevacizumab3. Its ability also to bind other related 
proangiogenic factors such as VEGF-B and the placental growth factors, PlGF1 and PlGF2 
makes this agent an appealing anti-angiogenesis drug for ccRCC. Aflibercept has been 
reported to have preclinical activity in several tumor models including renal cell carcinoma 
and has been approved for the treatment of colon carcinoma in combination with 
chemotherapy4–6.
In the present study we evaluated the efficacy and safety of two doses of aflibercept in the 
treatment of patients with metastatic ccRCC who had progressive disease after tyrosine 
kinase inhibitor (TKI) therapy.
Methods
Study design and participants
Eligible patients were 18 years or older with histologically confirmed metastatic or 
unresectable ccRCC with measurable lesions per Response Evaluation Criteria In Solid 
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Tumors (RECIST) criteria. Patients also had evidence of progressive disease following a 
prior VEGF receptor TKI treatment received for at least 12 weeks; an Eastern Cooperative 
Oncology Group (ECOG) performance status between 0–2; adequate organ function as 
measured by appropriate blood chemistries; and recovered from any toxic effects of prior 
radiotherapy or surgical procedures within 4 weeks prior to randomization. No prior cellular 
therapy, vaccine, hormonal, or chemotherapy was allowed. HIV-positive patients receiving 
ART were also excluded due to pharmacokinetic interactions with aflibercept; patients with 
history of metastatic CNS, pulmonary embolism, DVT, or other thromboembolic events 
were excluded. Patients were randomized into two treatment arms (A and B) to determine 
the effect of two different doses of aflibercept. Randomization was stratified by MSKCC7 
risk category and prior cytokine therapy.
Patients randomized to Arm A received 4mg/kg of aflibercept, on Day 1 of every 14-day 
cycle, intravenously over 1 hour into a peripheral vein or central venous catheter using an 
infusion pump. Patients in Arm B received 1mg/kg using the same schedule and infusion 
method (Figure 1). Tumor status was assessed every 8 weeks (every 4 cycles) after starting 
treatment. Tumor progression was defined using RECIST criteria. At the time of 
progression, the dose of patients in Arm B was escalated to 4mg/kg. A patient continued 
receiving protocol treatment until he/she developed progressive disease or unacceptable 
toxicity and all patients, including those who discontinued protocol therapy early, were 
followed for response until progression and for survival for 3 years from the date of 
randomization. Aflibercept was supplied by Aventis Pharmaceuticals and Regeneron, and 
distributed by Cancer Trials Evaluation Program (CTEP) of the Division of Cancer 
Treatment and Diagnosis (DCTD), National Cancer Institute (NCI). The ClinicalTrials.gov 
identifier for this study is NCT00357760.
Statistical analysis
The primary endpoint was defined as the proportion of patients alive and progression-free at 
8 weeks. Progression-free survival was defined as time from randomization to the earlier of 
documentation of progression or death. Patients alive and progression-free at the time of 
analysis were to be censored at the date of last disease assessment without evidence of 
progression. Extensive data on progression-free survival among patients who have 
previously been treated with TKI was not available at the time the study was designed. In 
this study, a progression-free proportion of 50% at 8 weeks was not of interest, while a 
proportion at 8 weeks of 67% signified that aflibercept was worthy of further study. 
Assuming an exponential distribution, this corresponds to an improvement in median 
progression-free survival from 8 weeks to 14 weeks.
A two-stage design was used within each arm. In the first stage, 33 eligible patients were 
accrued. If 16 or fewer patients were progression-free at 8 weeks, then the arm was to be 
closed. If at least 17 patients were progression-free at 8 weeks, then an additional 24 eligible 
patients would be accrued. If at least 34 of 57 eligible patients were progression-free at 8 
weeks, the dose would be considered worthy of further study. Using this design, the 
probability on each arm of declaring a dose unworthy of further study was 91% (statistical 
power) if the true 8-week progression free rate was 50% and 10% (Type I error) if the true 8-
Pili et al. Page 3
Clin Genitourin Cancer. Author manuscript; available in PMC 2018 December 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
week progression-free rate was 67%. To assure 33 and 24 eligible patients in the two stages 
of accrual, 35 and 25 patients, respectively, were to be randomized per stage and dose level 
for a total maximum of 60 patients per treatment arm.
Secondary endpoints were objective response rate, toxicity, response duration, and overall 
survival. A true objective response rate of 10% was of interest, whereas a true rate of 1% 
was not. Given 57 eligible patients per arm, the response rate would be considered 
interesting if 3 or more patients achieved an objective response. All patients receiving 
treatment, regardless of eligibility, were included in the assessment of toxicity. This study 
used Common Terminology Criteria for Adverse Events (CTCAE) Version 3 definition and 
only events with CTCAE attribution of possibly, probably, or definitely are reported. 
Response duration was defined as the time, in weeks, from onset of treatment response to 
disease progression. Patients without documented progression were censored at the date of 
last follow-up.
The efficacy analysis population included all eligible and treated patients. All treated 
patients, regardless of eligibility, were included in the toxicity analysis. The Kaplan-Meier 
(KM) method8 was used to describe overall and progression-free survival. Descriptive 
statistics was used to summarize patient characteristics at baseline. Two-sided 90% exact 
binomial CIs were computed for the assessment of toxicity and response rate.
Results
The total patient accrual was 94. The study was activated on 12/21/2007 and suspended on 
03/27/2012 having reached its stage 1 accrual goal. The study was then reactivated on 
06/20/2012 and only Arm A reopened to accrual – Arm B remained suspended and 
subsequently closed for failing to meet protocol specified efficacy criteria for continuation to 
stage 2. A total of 35 patients were accrued to Arm B by the end of stage 1; 3 of these 35 
patients were ineligible for efficacy analysis of PFS. The number of patients alive and 
progression-free at 8 weeks was 16 (50%) and thus Arm B did not meet the criteria for 
continuing to stage 2 accrual. Fifty-nine (59) patients were accrued to Arm A by the end of 
stage 2 and the study was terminated on 12/06/2013. Figure 2 shows this trial’s CONSORT 
diagram.
Patient Characteristics
Table 1 shows demographic and prognostic characteristics of patients in both treatment 
arms. The median age was 60 and 62 years respectively for patients in Arm A and B. More 
than 90% of patients in both treatment arms had an ECOG performance status of 0 or 1. The 
randomization process was effective in ensuring that patients in the treatment arms were 
comparable with respect to demographic and prognostic factors using appropriate statistical 
tests.
Toxicity
Table 2 provides a summary of treatment-related toxicities of all grades. The denominator 
included patients who received protocol therapy irrespective of eligibility status. The most 
common treatment-related toxicities in Arm A were fatigue (63%), hypertension (54%), 
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proteinuria (47%) and anorexia (39%). The proportion (90% CI) of severe (Grade of 3 or 
higher) toxicity in Arms A and B was 61.4% (49.7, 72.2) and 52.9% (37.7, 67.8) 
respectively. One patient in treatment Arm B experienced a grade 5 event described as 
intracranial hemorrhage. There were 10 grade 5 events (6 in treatment Arm A and 4 in Arm 
B) but were considered unrelated to treatment – 6 were due to disease progression and 4 
each due to renal failure, dyspnea, infection, and upper respiratory tract related toxicity.
Efficacy
As estimated from Kaplan Meier survival estimates, the proportion of patients alive and 
progression-free at 8 weeks (90% CI) was 70% (59, 79%) in treatment Arm A and 52% (37, 
66%) in Arm B. The proportion alive and progression free estimate of 70% for Arm A was 
higher than the proportion of interest value of 67% specified in the protocol. Likewise, the 
number of patients alive and progression free at 8 weeks was 39 which was higher than the 
protocol pre-specified number of 34 patients suggesting worthiness for further study. The 
PFS curve is shown in Figure 3. The estimated median PFS for treatment Arms A and B 
patients were 10.86 and 8.29 weeks respectively. The p-value of the log rank test comparing 
PFS between arms is 0.37; however this study was not powered to detect difference in PFS. 
A total of 52 (91%) events occurred among patients in treatment A and 31 (97%) in 
treatment B. Table 3 shows overall response by treatment arm among patients who were 
eligible and treated. The response rates with 90% CI for Arms A and B were 5.3% (1.4, 
13.0) and 3.1% (0.2, 14.0), respectively. The pre-specified number of objective responses of 
interest (≥ 3 patients) was satisfied in Arm A, suggesting efficacy. Waterfall plots of 
maximum percent change from baseline in the sum of lesions longest diameter for both 
treatment arms are shown in Figure 4. A reference line at −30% represents the RECIST 
criteria cutoff corresponding to a partial response (PR) to treatment. A patient in Arm B was 
identified as having progressive disease despite having about 70% reduction in lesion size 
because the patient developed multiple new lesions. Four (4) patients, from both treatment 
arms, experienced an objective response, the KM estimated median response duration (90% 
CI) among these four patients was 43.9 (31.4, 56.4) weeks. The median response duration 
among patients (n=23) with stable disease was 13.0 (8.1, 22.6) weeks. Sixteen (16) patients 
in treatment Arm B (1mg/kg) had their dosage escalated to 4mg/kg after disease 
progression. The median PFS (90% CI) before and after escalation were 8.6 (8.0, 14.0) 
weeks and 14.6 (7.6, 33.0) weeks respectively (Figure 5). An overall survival curve for 
eligible and treated patients is shown in Figure 6. The OS and PFS curves for all randomized 
patients (Supplementary Fig. 1 A and B) were estimated to confirm that survival experience 
did not considerably differ between all randomized and only eligible, treated patients.
Discussion
The results from this study confirm the hypothesis that continuous VEGF blockade 
following disease progression VEGF RTKIs may have clinical benefit in ccRCC patients. 
This study met the protocol specified criteria for significant improvement in progression-free 
survival among Arm A patients only (PFS of ≥ 0.67 and ≥ 34 patients alive and progression-
free at 8 weeks). Also, the protocol specified criterion for objective response was met among 
Arm A patients only (≥3 patients with response). Overall, the treatment was well tolerated, 
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though there was a greater percentage of patients who experienced treatment-related, grade 3 
or higher, toxicities in Arms A as compared to Arm B.
The treatment landscape for ccRCC is rapidly evolving9. The recent approval of two new 
multi-kinase inhibitors in the second line setting such as cabozantinib and lenvatinib 
suggests that sequential inhibition of additional tyrosine kinases besides VEGF RTKs may 
induce clinical benefit10,11. The treatment options for ccRCC are also significantly 
expanding due to the approval and clinical development of PD1/PD-L1 inhibitors12. 
Continuous VEGF inhibition remains an important tool to induce prolonged clinical 
response in ccRCC patients. The original approval of axitinib has validated retrospective 
studies suggesting that sequencing of TKIs can still induce disease control despite 
progression following frontline therapies with anti-VEGF therapies13. The VEGF ligand 
blocker bevacizumab has been approved in combination with interferon α for the treatment 
of renal cell carcinoma in the first line setting based on the results of two Phase III 
randomized studies14,15. Different combination strategies with bevacizumab have been also 
tested but these have been hampered by toxicities, and did not show greater efficacy as 
compared to single agent bevacizumab16. The assessment of the role of bevacizumab in the 
second and third line setting in RCC patients has been relatively limited. One report showed 
an ORR of 9% and a median PFS of 4.4 months in previously treated ccRCC patients17. In 
our study, the median PFS, ORR and toxicity profile observed in patients randomized to the 
either the 4 mg aflibercept arm or in those who crossed over to that dose appear similar to 
the historical data attributed to bevacizumab in the same setting. Thus, the results from our 
clinical trial are consistent with a dose-dependent benefit of aflibercept that was evident also 
in the crossed-over patients. Similar dose-dependent effect was observed also in the original 
single-agent study with bevacizumab in RCC18.
As the armamentarium for treating ccRCC is growing it becomes challenging to position 
new drugs in the current treatment algorithm. Aflibercept has shown preclinical more potent 
and broader activity than bevacizumab4. Identifying patients who may most benefit from the 
pharmacodynamics of aflibercept may represent a clinically relevant question. As HIF-2α 
antagonists are becoming available, a potential combination with an effective VEGF blocker 
such as aflibercept appears a rational strategy for ccRCC19,20.
Conclusions
This study confirms the potential benefit of VEGF blockade in previously treated patients 
with metastatic ccRCC. Aflibercept shows evidence of activity in previously treated ccRCC 
and may be worthy of further study in rational combination strategies where continuous 
VEGF blockade may be beneficial.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Clinical Practice Points
• The treatment of metastatic ccRCC is rapidly evolving but therapies targeting 
the VEGF axis remain the main treatment of this disease.
• The use of the VEGF blocker aflibercept in pretreated ccRCC patients was 
safe and showed clinical benefit.
• Rational combination strategies with aflibercept may be beneficial in ccRCC 
patients.
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Figure 1. 
Study Schema
NOTE: Aflibercept dosing is based on actual weight.
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Figure 2. 
CONSORT diagram (with patient flow)
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Figure 3. 
Progression-Free Survival for Eligible and Treated Patients
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Figure 4. 
Waterfall Plots of Maximum Decrease in Sum of Lesions’ Longest Diameter by Treatment 
Arm
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Figure 5. 
Progression-Free Survival before and after Dose Escalation (1mg/kg to 4mg/kg)
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Figure 6. 
Overall Survival of Eligible and Treated Patients
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Table 1
Patient Demographics at Baseline
Variable
Treatment Arm N(%)
Arm A (n=57) Arm B (n=32)
Age
 Median 60 62
 (Min, Max) (35,80) (33,73)
 Mean ± SD 59.7 ± 10.4 60.2 ± 9.0
Sex
 Male 43 (75.4) 22 (68.7)
 Female 14 (24.6) 10 (31.3)
Race
 White 54 (94.7) 31 (96.9)
 Black 3 (5.3) 1 (3.1)
ECOG Performance Status
 0 28 (49.1) 15 (46.9)
 1 26 (45.6) 15 (46.9)
 2 3 (5.3) 2 (6.2)
Renal Histology Type
 Clear Cell Carcinoma 53 (93.0) 31 (96.9)
 Mixed 4 (7.0) 1 (3.1)
Pre-Registration Evaluation
 Progressive Disease 57 (100) 32 (100)
Prior Disease Treatment
 Surgery 16 (28.1) 10 (31.3)
 Nephrectomy 52 (91.2) 26 (81.3)
 Radiation therapy 15 (26.3) 10 (31.3)
 Immunotherapy 6 (10.5) 3 (9.4)
 Sunitinib 47 (82.5) 30 (93.8)
 Sorafenib 14 (24.6) 6 (18.8)
 Interleukin 2 (IL2) 5 (8.8) 3 (9.4)
 Pazopanib 8 (14.0) -
 Interferon 1 (1.8) -
 Axitinib 3 (5.3) -
 Other TKI Anti-VEGF 3 (5.3) -
 Other Prior Therapy 8 (14.0) 7 (21.9)
Metastatic Sites
 Bone 22 (38.6) 9 (28.1)
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Variable
Treatment Arm N(%)
Arm A (n=57) Arm B (n=32)
 Liver 16 (28.1) 7 (21.9)
 Lung 49 (86.0) 19 (59.4)
 Brain - -
 Pleura 8 (14.0) 3 (9.4)
 Subcutaneous 5 (8.8) 1 (3.1)
 Lymph Nodes 36 (63.2) 20 (62.5)
 Other 16 (28.1) 15 (46.9)
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Table 3
Best Overall Response
Best Overall Response
Treatment Arm
Arm A (4 mg/kg) Arm B (1 mg/kg)
n (%) n (%)
Overall Response (OR) 3 (5.3) 1 (3.1)
Complete response (CR) - -
Partial response (PR) 3 (5.3) 1(3.1)
No change/Stable 16 (28.1) 7 (21.9)
Progression (PD) 26 (45.6) 19 (59.4)
Unevaluable 12(21.0) 5 (15.6)
Total 57 32
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